In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility

被引:32
作者
Giovanetti, E
Montanari, MP
Marchetti, F
Varaldo, PE
机构
[1] Univ Ancona, Inst Microbiol, I-60131 Ancona, Italy
[2] Hoechst Marion Roussel, Dept Med Sci, I-20020 Lainate, Italy
关键词
D O I
10.1093/jac/46.6.905
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Two ketolides, telithromycin and HMR 3004, were evaluated for their in vitro activity against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes and Streptococcus pneumoniae. On the basis of their resistance to macrolide, lincosamide and streptogramin (MLS) antibiotics, erythromycin-resistant test strains were assigned to the constitutive resistance (cMLS) phenotype, the inducible resistance (iMLS) phenotype or the Rn phenotype. iMLS S. pyogenes strains were further subdivided into the three recently described subtypes iMLS-A, -B and -C. Telithromycin and HMR 3004 were uniformly and highly active against pneumococci (regardless of their susceptibility or resistance to erythromycin and/or penicillin), erythromycin-susceptible S, pyogenes and erythromycin-resistant S. pyogenes strains of the M phenotype (in which resistance is mediated by an efflux system) or iMLS-B or -C phenotype (in which resistance is mediated by a methylase encoded by the ermTR gene). Both ketolides were less active against erythromycin-resistant S. pyogenes strains with the cMLS phenotype or the iMLS-A subtype (where resistance is mediated by a methylase encoded by the ermAM gene), these strains ranging in phenotype from the upper limits of susceptibility to low-level resistant.
引用
收藏
页码:905 / 908
页数:4
相关论文
共 15 条
[1]   Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens [J].
Agouridas, C ;
Bonnefoy, A ;
Chantot, JF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2149-2158
[2]  
BARRY AL, 1998, 4 INT C MACR AZ STRE, P20
[3]   Ketolides lack inducibility properties of MLSB resistance phenotype [J].
Bonnefoy, A ;
Girard, AM ;
Agouridas, C ;
Chantot, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :85-90
[4]  
Bryskier A, 1997, INFEC DIS T, V21, P39
[5]   Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains [J].
Giovanetti, E ;
Montanari, MP ;
Mingoia, M ;
Varaldo, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1935-1940
[6]   The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA [J].
Hansen, LH ;
Mauvais, P ;
Douthwaite, S .
MOLECULAR MICROBIOLOGY, 1999, 31 (02) :623-631
[7]   Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae [J].
Jones, RN ;
Cormican, MG ;
Wanger, A .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 25 (04) :201-204
[8]   Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy [J].
Marchese, A ;
Tonoli, E ;
Debbia, EA ;
Schito, GC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) :461-464
[9]   A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin [J].
Rosato, A ;
Vicarini, H ;
Bonnefoy, A ;
Chantot, JF ;
Leclercq, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1392-1396
[10]   Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin [J].
Rosato, A ;
Vicarini, H ;
Leclercq, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :559-562